Pyrovalerone
Encyclopedic
Encyclopedic
Typical encyclopedia coverage. Cross-reference for important decisions.
- 2 corroborating sources
- 4 ROAs with full dose ladders
- duration data present
- 18 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
- 2 corroborating sources
- 4 ROAs with full dose ladders
- duration data present
- 18 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
Aliases: O-2371, Centroton, Thymergix, 4-methyl-Ξ²-keto-prolintane
Summary
Pyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile between methylphenidate and MDPV, with strong drive to redose every 2-3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity.
Dose Information
Dose basis. Numbers are compiled from scattered user reports; not supported by formal pharmacology. Interindividual variability appears high within this class; treat all figures as tentative and start very low. Consider volumetric dosing for accurate measurement of low-milligram powders. Insufflation increases cardiovascular strain and compulsive redosing versus oral; burning/irritation common. Doses are anecdotal; start below βlightβ. (Dose figures and this note are from Drugs.Wiki.)
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 10-25mg | 25-60mg | 60-100mg | 100mg+ |
| Insufflated | 5-15mg | 15-40mg | 40-80mg | 80mg+ |
| Rectal | 5-15mg | 15-35mg | 35-70mg | 70mg+ |
| Intravenous | 1-5mg | 5-15mg | 15-30mg | 30mg+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | Total |
|---|---|---|---|---|---|
| Oral | 10-30 min | 30-60 min | 30 min | 1-3 hrs | 2.17-5 hrs |
| Insufflated | 5-10 min | 15-30 min | 30 min | 1-3 hrs | 1.83-4.17 hrs |
| Rectal | 10-20 min | 20-40 min | 30 min | 1-3 hrs | 2-4.5 hrs |
| Intravenous | 2 min | 2-5 min | 30 min | 1-3 hrs | 1.56-3.61 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Strong anxiety/jitters with mild stimulation and euphoria, low focus
Add to PsychonautWiki Journal
The PsychonautWiki Journal logging app doesn't include every substance. To track Pyrovalerone there, start adding an ingestion, search for the name, and choose to add it as a custom substance. Paste these values:
Pyrovalerone Source: SubstanceSearch (substancesearch.com) Oral dose (mg): threshold 5-10 Β· light 10-25 Β· common 25-60 Β· strong 60-100 Β· heavy 100+ Insufflated dose (mg): threshold 3-5 Β· light 5-15 Β· common 15-40 Β· strong 40-80 Β· heavy 80+ Rectal dose (mg): threshold 3-5 Β· light 5-15 Β· common 15-35 Β· strong 35-70 Β· heavy 70+ Intravenous dose (mg): threshold 0.5-1 Β· light 1-5 Β· common 5-15 Β· strong 15-30 Β· heavy 30+ Oral duration: onset 10-30m Β· come-up 0.5-1h Β· peak 30m Β· offset 1-3h Β· total 2.17-5h Β· after-effects 2-24h Insufflated duration: onset 5-10m Β· come-up 15-30m Β· peak 30m Β· offset 1-3h Β· total 1.83-4.17h Β· after-effects 2-24h Rectal duration: onset 10-20m Β· come-up 20-40m Β· peak 30m Β· offset 1-3h Β· total 2-4.5h Β· after-effects 2-24h Intravenous duration: onset 2m Β· come-up 2-5m Β· peak 30m Β· offset 1-3h Β· total 1.56-3.61h Β· after-effects 2-24h Note: ranges are harm-reduction guidance, not a prescription. Start low, go slow, and test your substances.
Tip: for quicker logging you can also add a Custom Unit in the app, e.g. common dose ~ 42.5 mg (Oral).
The app keeps custom substances simple, so the full dose ranges live in the description text above. Ranges are harm-reduction guidance, not a prescription.
Tolerance
Tolerance Decay
Acute tolerance: develops within a single session β the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Model is an anecdotal approximation based on pyrrolidinophenone user reports: rapid escalation during binges with partial recovery over several days; crossβtolerance within the class is expected given shared DAT/NET inhibition. Treat this as a planning aid for spacing sessions, not a guarantee. Data quality: anecdotal/communityβderived.
Cross-Tolerances
Effects
- Stimulation
- Increased Energy
- Teeth grinding
- Increased heart rate
- Pupil Dilation
- Jaw Tension
- Restlessness
- Difficulty Sleeping
- Motivation enhancement
- Euphoria
- Enhanced Sociability
- Anxiety
- Compulsive redosing
- Irritability
- Depression
- Increased focus
- Talkativeness
- Increased libido
- Tactile enhancement
- Increased music appreciation
- Appetite suppression
- Light sensitivity
- Disinhibition
- Dehydration
- Vibrating vision
- Increase sexuality
Combinations
Cross-Check Pyrovalerone with another substanceHelpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for Pyrovalerone? Let us know. Reports are reviewed by moderators — this is not posted publicly.